Med. praxi. 2026;23(1):28-32 | DOI: 10.36290/med.2025.072

Adrenal incidentalomas: management approach

doc. MUDr. Ondřej Petrák Ph.D., prof. MUDr. Tomáš Zelinka, CSc.
Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze
III. interní klinika VFN a 1. LF UK v Praze

Incidentalomas are adrenal masses detected on imaging performer for reasons other than suspected adrenal disease. They include a wide spectrum of diagnoses from completely benign and insignificant findings to hormonally active tumors, to possible rare adrenal cortex carcinoma or metastatic disease. The following article contains a basic diagnostic and therapeutic approach considering currently valid European guidelines on management of adrenal incidentalomas. It includes several basic considerations, namely when to think about malignancy and hormonally active form, when to operate and how follow up the patient.

Keywords: adrenal incidentaloma, pheochromocytoma, primary hyperaldosteronism, hypercortisolism, MACS, adenoma, adrenal cortex carcinoma, myelolipoma.

Received: April 8, 2025; Revised: September 18, 2025; Accepted: October 3, 2025; Published: March 3, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petrák O, Zelinka T. Adrenal incidentalomas: management approach. Med. praxi. 2026;23(1):28-32. doi: 10.36290/med.2025.072.
Download citation

References

  1. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. Jul 20 2023;189(1):G1-G42. doi:10.1093/ejendo/lvad066. Go to original source... Go to PubMed...
  2. Lenders JWM, Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. Aug 2020;38(8):1443-1456. doi:10.1097/HJH.0000000000002438. Go to original source... Go to PubMed...
  3. Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. Oct 2020;38(10):1919-1928. doi:10.1097/HJH.0000000000002510. Go to original source... Go to PubMed...
  4. Deutschbein T, Reimondo G, Di Dalmazi G, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol. Jul 2022;10(7):499-508. doi:10.1016/S2213-8587(22)00100-0. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.